Dynamic Technology Lab Private Ltd reduced its position in shares of LivaNova PLC (NASDAQ:LIVN) by 17.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,326 shares of the company’s stock after selling 702 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in LivaNova were worth $251,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the stock. Texas Permanent School Fund grew its stake in LivaNova by 0.5% during the 4th quarter. Texas Permanent School Fund now owns 33,106 shares of the company’s stock worth $2,497,000 after buying an additional 169 shares during the last quarter. Strs Ohio lifted its holdings in shares of LivaNova by 1.0% during the fourth quarter. Strs Ohio now owns 19,600 shares of the company’s stock valued at $1,478,000 after purchasing an additional 200 shares during the last quarter. State of Michigan Retirement System lifted its stake in LivaNova by 1.4% in the 4th quarter. State of Michigan Retirement System now owns 14,200 shares of the company’s stock worth $1,071,000 after acquiring an additional 200 shares in the last quarter. Advisor Group Inc. lifted its stake in LivaNova by 9.3% in the 4th quarter. Advisor Group Inc. now owns 2,714 shares of the company’s stock worth $205,000 after acquiring an additional 231 shares in the last quarter. Finally, American International Group Inc. lifted its stake in LivaNova by 0.3% in the 4th quarter. American International Group Inc. now owns 123,057 shares of the company’s stock worth $9,282,000 after acquiring an additional 345 shares in the last quarter. 91.54% of the stock is currently owned by institutional investors and hedge funds.
LIVN has been the topic of several research reports. Stifel Nicolaus dropped their target price on LivaNova from $80.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday. Berenberg Bank reaffirmed a “buy” rating and issued a $114.00 target price on shares of LivaNova in a report on Thursday, February 27th. Canaccord Genuity reaffirmed a “hold” rating and issued a $66.00 target price on shares of LivaNova in a report on Thursday, February 27th. ValuEngine downgraded LivaNova from a “buy” rating to a “hold” rating in a research report on Tuesday, March 17th. Finally, Zacks Investment Research downgraded LivaNova from a “hold” rating to a “sell” rating in a research report on Wednesday, March 4th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $84.57.
In other news, CEO Damien Mcdonald sold 1,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $68.00, for a total value of $68,000.00. Following the sale, the chief executive officer now directly owns 64,016 shares in the company, valued at $4,353,088. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.41% of the company’s stock.
NASDAQ:LIVN opened at $40.93 on Thursday. LivaNova PLC has a 1 year low of $33.40 and a 1 year high of $99.13. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.22. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of 13.91, a PEG ratio of 2.46 and a beta of 0.37. The stock has a 50-day moving average price of $63.78 and a two-hundred day moving average price of $72.67.
LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, February 26th. The company reported $1.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.02. The firm had revenue of $287.60 million during the quarter, compared to analysts’ expectations of $295.49 million. LivaNova had a positive return on equity of 9.47% and a negative net margin of 14.31%. The company’s revenue was down 3.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.12 earnings per share. Sell-side analysts forecast that LivaNova PLC will post 3.14 earnings per share for the current year.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Featured Article: Dividend
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN).
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.